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ORIGINAL ARTICLE
Evolution of testosterone treatment over 25 years: symptom responses,
endocrine profiles and cardiovascular changes
Malcolm Carruthers1,2, Paul Cathcart3, and Mark R. Feneley3
1Centre for Men’s Health, London, UK, 2Alzheimer’s and Ageing Department, Edith Cowan University, Perth, WA, Australia, and 3Department of
Urology, University College Hospital, London, UK
Abstract
Introduction: Testosterone treatment has evolved rapidly over the past 25 years as new, more
effective and convenient methods have become available. This study reports experience with
seven different methods, introduced on the market in the UK.
Aim: To establish the symptom response when testosterone treatment was initiated on the
basis of clinical features and symptoms of androgen deficiency, and the resulting endocrine,
biochemical and physiological responses.
Methods: Of 2693 patients attending the 3 Men’s Health Centers – The UK Androgen Study
(UKAS), 2247 were treated. Treatments included pellet implants, oral testosterone undecanoate
(Testocaps), mesterolone (Proviron), testosterone gel (Testogel), testosterone scrotal cream
(Andromen) and scrotal gel (Tostran).
Results: There was no correlation between initial testosterone level, initial symptom score or
the success of treatment as defined by adequate resolution of symptoms. Despite the diverse
endocrine patterns produced, the testosterone preparations appear equally safe over
prolonged periods, with either no change or improvement of cardiovascular risk factors,
especially in lowering cholesterol and diastolic blood pressure.
Conclusions: It is suggested that because of excessive reliance on laboratory measures of andro-
gens and undue safety concerns, many men who could benefit from symptom relief, improve-
ment in related clinical conditions and given preventive medical benefits remain untreated.
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Nebido, symptom scales, Scrotal Tostran,
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Introduction
There is great debate about the indications for testosterone
treatment, its safety and effectiveness. Many generalizations
are made often without reference to the particular form used,
the endocrine changes they produce, their effects on cardio-
vascular risk factors and their relative suitability for different
clinical conditions.
Testosterone treatment has evolved greatly over the past
25 years becoming both safer and more effective. Not all
testosterone preparations are equal in terms of their endocrine
actions and side effects. Such factors need to be taken into
consideration in selecting an appropriate formulation for
testosterone replacement treatment (TRT).
Cost can also substantially influence prescribing practice in
some countries. This was illustrated in a paper earlier this year
on the ‘‘Population-based patterns of prescription androgen
use, 1976–2008’’ which found that the commonest form of
testosterone treatment in Canada during that period was methyl
testosterone at 36.2% [1]. This was similar to the prescription
rate seen in Russia, despite its long-recognized hepatotoxicity
and cardiotoxicity which caused it to be declared ‘‘obsolete’’
and taken-off the European market in the 1980s [2], and yet it is
still cheaply and widely available via the web in all countries.
A similar lack of practical clinical information about
another oral preparation being considered for marketing in
the US, testosterone undecanoate (Rextoro – Clarus
Pharmaceuticals), was shown when the FDA recently rejected
a new drug license for this, while calling for more data on
efficacy and safety, despite virtually the same formulation
being available in Europe, Canada and Australia for the last
30 years.
The present study was designed as a retrospective audit to
investigate the indications for treatment, symptomatic res-
ponses together with the endocrine, metabolic and cardiac risk
factor changes on seven different testosterone preparations,
illustrating the evolution of this treatment over 25 years.
This is an Open Access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivatives License (http://
creativecommons.org/Licenses/by-nc-nd/4.0/), which permits non-
commercial re-use, distribution, and reproduction in any medium,
provided the original work is properly cited, and is not altered,
transformed, or built upon in any way.
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Health, 96 Harley Street, London, W1G 7HY, UK. E-mail:
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Methods
The UK Androgen Study (UKAS) is an ongoing analysis of
patients attending the Centre for Men’s Health clinics in
London, Manchester and Edinburgh since they were estab-
lished in 1989. Ethical permission for this audit was obtained
from the St. Mary’s Hospital Local Research Ethics
Committee (LREC), with informed consent from the patients
for the use of their anonymized data.
Though treatment within this clinical practice could not be
blinded, and bias in the subjective reporting cannot therefore
be excluded, every effort has been made to make the
observations as objective as possible. First visit data served
as the control in each patient, for comparison with data from
subsequent visits, which were usually at 6 monthly intervals
once treatment had been optimized by dosage adjustment
according to symptomatic response.
The study was initiated 25 years ago, before diagnostic
guidelines for testosterone treatment had been established.
Patients were diagnosed with androgen deficiency based on
history, clinical assessment, Andropause Check List (ACL)
and Aging Male Symptoms (AMS) [3] scores. The ACL is a
detailed testosterone deficiency symptom scale comprising 20
questions rated on a five-point scale of 0 – none, 1 – mild, 2 –
moderate, 3 – severe, 4 – very severe or total [4]. It is based
on the characteristic symptoms described nearly 70 years ago
by Dr August Werner and correlates closely with other
descriptions of the symptoms and rating scales, including the
AMS scale developed 15 years ago, with which many items
overlap (r¼ 0.731). The ACL was used at each subsequent
visit to monitor symptom response to treatment. With a
maximum score of 80, a total of 10 or less was rated as
normal and was the target for treatment. Seven different
testosterone preparations were used, and some patients
changed treatment groups to achieve symptom remission.
Full endocrine, biochemical and hematological profiles
were available to guide treatment and monitor its safety,
together with the clinical and physiological data recorded at
each visit. The laboratory data are taken according to the
hospital and major independent laboratories reporting them,
all using full quality control procedures and standard guide-
lines. The laboratory data were entered directly into an Access
database via secure electronic data link, to prevent transcrip-
tion errors. Fasting blood samples were taken between 9 and
11 am to minimize the variables which can otherwise
invalidate androgen assays and to get a clearer picture of
changes in lipid and carbohydrate metabolism with treatment.
They were also taken prior to digital or ultrasound trans-rectal
examination of the prostate.
The endocrine profile included total testosterone (TT), sex
hormone binding globulin (SHBG), calculated free testoster-
one (cFT), estradiol (E2), luteinizing hormone (LH), follicle
stimulating hormone (FSH), and cFT was determined using
the Vermeulen formula [5]. The biochemical profile included
total and free prostate specific antigen (PSA), free/total PSA
ratio, standard renal function tests and estimated glomerular
filtration rate (eGFR), liver function tests, uric acid, iron,
fasting glucose, triglycerides and total cholesterol, together
with HDL, total cholesterol/HDL ratio and LDL. The
hematology profile included hemoglobin and indices to
exclude polycythemia, white cell count and differential
platelets, and erythrocyte sedimentation rate (ESR). Routine
urine chemistry was also performed at each visit.
The data were collated using a computerized practice
management system called the Global Andrology Assessment
and Treatment Tracking program (GAATT), developed spe-
cifically for use in the Centre for Men’s Health. This program
assembled the information on all patients in an Access
(Microsoft) database, and then extracted it using a data
mining program, by which individual or group responses to
treatment could be assessed.
Statistical tests were performed using the PASW (SPSS) 22
statistics program. Results for the endocrine data were log-
transformed for analysis, because it is now recognized that as
with most endocrine data, a skewed distribution must be
normalized prior to analysis. The before and after treatment
logged endocrine and PSA data, and other measures were
analyzed by paired Student’s t tests. Logistic regression
analysis compared baseline and final testosterone, estrogen
and SHBG levels with treatment response failure. The failure
event was defined by persistence of symptoms with an ACL
symptom score over 10 on testosterone replacement when that
particular treatment was discontinued. A Cox regression
model was used to calculate adjusted hazard ratios (HRs) for
response failure, comparing the different testosterone prepar-
ations. These analyses were performed using STATA version
11 (StataCorp, College Station, TX).
Exclusion criteria
As the intention was to study the diagnosis and treatment of
secondary testosterone deficiency, certain groups of patients
were excluded:
(1) Primary testosterone deficiency, e.g. cases with a history
of non-descent of testes, bilateral orchidectomy or
patients diagnosed as Klinefelter’s Syndrome.
(2) Prostate or breast cancer, or suspected prostate cancer.
(3) Asymptomatic men attending for general medical
screening.
(4) Men seeking physical fitness training. Anabolic steroid
treatment is not offered at the clinic to young men
seeking improvement in athletic performance or physique
(5) Young men with anxiety symptoms described as ‘‘locker
room syndrome’’.
(6) Men diagnosed as ‘‘Male Mid-life Crisis’’.
(7) Patents with a primary diagnosis of depression.
Results
2693 patients attended the three centers, being were either
self-referred or sent by their physicians the UK Androgen
Study (UKAS). On the basis of their symptoms, history and
clinical findings, 2247 men were diagnosed as androgen
deficient and given testosterone treatment. Their mean age
was 54 years, range 24–90, 93% being Caucasian, and median
follow-up was 1 year (mean 1.6 years). Often symptoms of
testosterone deficiency, including loss of libido and energy,
erectile dysfunction, loss of morning erections, night sweats,
joint pains, depression, irritability and impaired memory had
been present for 3–5 years prior to attending the clinics for the
first time.
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The distribution of the initial pre-treatment testosterone
levels are shown in Figure 1(a,b) and together with the
other variables baseline levels served as controls for the later
values. This audit enabled total and free testosterone to be
evaluated as criteria for the diagnosis of androgen deficiency
and as predictors of ability to achieve a full symptomatic
response on treatment.
As the initial diagnosis was made on the basis of clinical
features and symptoms alone, all symptomatic patients were
given a therapeutic trial of testosterone treatment. Many of
these patients had previously been declined treatment by their
doctors on the basis of a testosterone level in the ‘‘normal’’
range even though this varies between laboratories, and
reliability is susceptible to many factors [6]. Their ‘‘normal
ranges’’ are poorly defined not only because of the diurnal
variation and age-related decline in testosterone levels, but
particularly because they do not take account of the log-
normal distribution. This changes both the mean and range, as
shown by the distribution of the patient’s pre-treatment
testosterone levels (Figure 1a,b).
In this study, TT and cFT are totally unrelated to the initial
symptom score, which was the reason for patients attending
Figure 1. (a) Pre-treatment total testosterone
levels, showing marked skewing to the left of
the normal distribution curve. (b) The log-
normal distribution of all pre-treatment blood
total testosterone levels.
DOI: 10.3109/13685538.2015.1048218 Evolution of testosterone treatment 219
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the clinic for treatment. This is shown in Figure 2. Also, there
is no association between initial symptom score and baseline
estradiol or SHBG. These findings are consistent with those
in other studies showing failure of endocrine assays to
correlate with symptoms [7,8].
In this series, overall only 2% of pre-treatment TT
levels were below 6 nmol/l (173 ng/dl), 6% below 8 nmol/l
(230 ng/dl), 17% below 10 mol/l (288 ng/dl), 31% below
12 nmol/l (346 ng/dl), 45% below 14 nmol/l (404 ng/dl) and
58% below 16 nmol/l 460 ng/dl). These are all commonly used
cut-off points required for the diagnosis of ‘‘hypogonadism’’,
though the higher levels are increasingly accepted [9].
Comparing the symptomatic responses to treatment for the
31% of patients with initial TT levels below 12 (mean
9.6 nmol/l) with those greater than or equal to 12 (mean
19.1 nmol/l), there was no significant difference found
between either the initial symptom scores (mean 26.7 and
26.1, respectively) or their response to treatment for up to 12
years for all forms of treatment (Figure 3).
Logistic regression analysis of failure to achieve a full
symptomatic response also found no association with pre-
treatment TT. Also, no statistically significant association is
found between final TT, cFT, oestradiol or SHBG and the
failure to achieve a full symptomatic response on any
particular treatment. Unadjusted 1-year symptom failure is,
however, strongly associated with the severity of presenting
symptoms, increasing from only 12% for patients with the
least severe symptom score prior to commencing testoster-
one replacement therapy to 59% for patients with the most
severe symptoms prior to replacement therapy, a finding
that was highly statistically significant (HR 4.6, 95% CI
2.6–8.0, p50.001). In those patients who did not achieve
complete symptom response, many nevertheless continued
on treatment with significant symptomatic benefit compared
to baseline.
Treatment groups
As seen in Tables 1–3, there were markedly different changes
in endocrine, metabolic and cardiac risk factor changes with
the various preparations, so each is considered separately for
the seven treatment groups. Some patients changed dosage or
treatment groups to achieve optimal remission of symptoms,
which was the goal of treatment.
The treatments are considered in the order that they
appeared on the UK market. Their short-term endocrine,
biochemical and physiological effects are shown in
Tables 1–3 after 1 year of treatment, and thereafter there
were no progressive changes. Long-term endocrine effects are
shown in Figure 4a–g.
Figure 2. Lack of relationship between pre-
treatment total ACL symptom scores and
levels of total testosterone.
0
5
10
15
20
25
30
0 1 2 3 4 5 6 7 8 9 10 11 12
TT≥12
TT<12
Total Symptom  Score (ACL)
Treatment Years
Figure 3. Symptomatic response over 12 years for patients presenting
with TT 12 nmol/l and those412 nmol/l.
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Pellet implants (TI)
This is considered first because it is the oldest form of
treatment studied, having been in use for over 70 years,
though it now being replaced in most clinical practices in
countries where it is available by testosterone undecanoate
injections (Nebido), which last 2–3 months. An improved
system using smaller pellets (Testopel) is available in the
USA [10].
This group received testosterone pellet implants (TI)
(Organon, 325 patients, 806 treatment years). These patients
Figure 4. Symptom response and endocrine changes on treatment with: (a) testosterone implant (TI) over a period of 12 years, (b) oral testosterone
undecanoate (TU) over a period of 10 years, (c) proviron (ME) over a period of 7 years, (d) Testogel (TG) over a period of 9 years, (e) Nebido (TJ) over
a period of 5 years, (f) Scrotal AndroForte (SA) over a period of 3 years and (g) Scrotal Tostran (ST) over a period of 5 years.
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had 4–10 of the 200-mg pellets of the fused crystals implanted
into alternate buttocks every 6 months. There was a marked
reduction in ACL symptom scores (Table 1; Figure 3a), under
10 being considered a satisfactory response. The dose needed
to maintain freedom from symptoms of testosterone deficiency
for a 6-month period varied widely between individuals,
but was relatively constant for each person, with different
thresholds of TT and cFT at which symptoms returned.
The endocrine measurements were taken at the end of the
implant period and are shown after 1 year, which includes two
implant cycles for dose stabilisation, as seen in Table 1, and
for up to 12 years as seen in Figure 4(a). Peak testosterone
levels are known to occur within a month of each implant-
ation, but the trough TT levels as measured here were still
significantly raised over baseline at 6 months, when the next
implant was due.
The SHBG was slightly decreased for up to 7 years, rising
to pre-treatment values after 9 years perhaps due to aging.
cFT was markedly raised, with both LH and FSH reduced to
very low levels throughout the implant cycle. There was
only a slight but significant increase in E2 throughout the
12 years of treatment, also more marked after 8 years.
There were slight but statistically significant decreases
in fasting glucose and triglyceride levels, but highly signifi-
cant reductions in total cholesterol, HDL and LDL but no
change in total cholesterol/HDL ratio (Table 2).
There was a slight increase in body mass index (Table 3)
and reduced diastolic blood pressure, with a raised pulse rate,
suggesting the vasodilatation seen with all the testosterone
preparations except for mesterolone. There was a highly
significant increase in hemoglobin and hematocrit again seen
with all preparations except mesterolone. These, however,
remained within the normal range in over 90% of cases, but
being included in the routine screen, polycythemia was
detected early and could be corrected by reducing the dose or
using another preparation.
Oral testosterone undecanoate (TU)
The largest treatment group was those receiving oral testos-
terone undecanoate (Restandol–Andriol Organon, 1016
patients, 2147 treatment years). The original preparation
was found to be temperature unstable and had to be
refrigerated to remain fully active for more than a month,
but was replaced by a bioequivalent stable form in castor oil
(Testocaps) in 2005. When taken with a meal containing fat,
absorption of 40–120 mg doses (1–3 40 mg capsules) via the
chylomicra in twice daily doses provided good clinical results
in most cases (Table 1). As with other preparations, the
dosage was varied to sustain optimum symptom relief, while
not exceeding the physiological range in non-fasting samples.
The endocrine changes on this preparation at 1 year are seen
in Table 1 and for up to 10 years in Figure 4(b).
Though the increase in TT measured was only small in
these fasting samples because of lack of absorption, cFT rose
significantly, mainly due to a large reduction in SHBG. There
was a significant decrease in E2, as well as LH and FSH,
which, however, usually remained within the physiologically
normal ranges.
Glucose did not change, but all lipid levels were decreased
(Table 2), though the total cholesterol/HDL ratio increased.
The BMI, systolic and diastolic blood pressures were
decreased, but pulse rate increased. Hemoglobin and hem-
atocrit were increased but less than with parenteral treatments
and again usually stayed within the normal range.
Mesterolone (ME)
The other oral treatment group was mesterolone (Proviron–
Bayer, 317 patients, 477 treatment years). For many patients,
this preparation, being converted entirely to DHT and
therefore only a partial form of androgen replacement, often
provided inadequate symptom relief, and was abandoned after
the first 5 years of the study.
The endocrine results are shown in Table 1 and
Figure 4(c). The paradoxical reduction in TT (p .012), with
no change in cFT, reflects a significant reduction in SHBG
due to the suppression of endogenous testosterone synthesis
by this form of treatment, as indicated by the slight decrease
in LH and FSH. Also, since this preparation cannot be
aromatized, there was a marked reduction in E2 which may
partly account for its weak clinical action.
Though BMI increased slightly, there were no changes in
glucose or triglyceride levels and smaller reductions in total
cholesterol, HDL, the ratio and LDL (Table 3). There was a
slight reduction in diastolic blood pressure and rise in pulse
rate, and as with the other preparations, hemoglobin and
hematocrit were unchanged.
Testosterone gel (TG)
When it became available 10 years ago, testosterone gel
(Testogel–Androgel–Bayer, 343 patients, 740 treatment
years), being a once-daily transdermal treatment with 5 G of
10% gel, was soon found to be highly acceptable and
clinically effective. Application to the axilla more than
doubled the absorption and when needed could avoid the
use of two sachets.
Large increases in TT and cFT, measured an average of 2 h
after the application of the gel, were maintained for up
to 24 h, as shown by the occasional patient who failed to
Figure 4. Continued.
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apply the gel on the day of the test, as well as by previous
studies [11] (Table 1; Figure 4d).
There was only a slight reduction in SHBG, while LH
and FSH levels were markedly suppressed, often to below the
limits of measurement. As well as the reported increase in
DHT [12], aromatization also produced a slightly greater
increase in E2 at 1 year than the other preparations (Table 1).
There was no change in glucose levels, but all lipids were
decreased (Table 2). Unlike other reports on the treatment
with non-genital testosterone gel [11], there was an increase
in BMI (Table 3), probably due to an increase in muscle mass.
As with the majority of other preparations studied, there was a
significant decrease in diastolic blood pressure and an
increase in pulse rate. Hemoglobin and hematocrit were
increased, again usually within the normal ranges.
Testosterone undecanoate injections (TJ)
Nebido (Reandron–Bayer, 49 patients, 85 treatment years; 1 g
injections in 4 ml castor oil) was used in this study over
5 years. The androgen levels measured here are trough values
6–12 weeks after injection, when symptoms were beginning
to return. This treatment has been shown to be safe and
effective in large-scale international studies over 8 years [13]
and has recently been approved in the USA as 0.75 g
testosterone undecanoate in 3 ml castor oil injections
(Aveed). Symptom relief was excellent and rapid, and there
were no adverse reactions apart from mild pain at the
injection site lasting 1–6 h.
Endocrine values as measured after 1 year, when symptoms
were returning at 6–12 weeks after the initial injection and
progressively longer intervals thereafter, showed the trough
levels of testosterone to be only moderately raised from pre-
treatment values, with no change in SHBG, but a significant
rise in CFT. E2 was slightly raised and there was a highly
significant suppression of LH and FSH (Table 1; Figure 4e).
Glucose and triglyceride levels were unchanged, and there
were slight reductions in total and HDL cholesterol, but no
change in LDL or the cholesterol/HDL ratio (Table 2).
There was no change in BMI or systolic blood pressure,
and a slight decrease in diastolic pressure, but unlike the other
preparations, no change in pulse rate. There were highly
significant increases in hemoglobin and hematocrit, but again
usually within the normal range (Table 3).
Scrotal AndroForte (SA)
Testosterone creams applied to the scrotum are found to be
over 10 times better absorbed through the scrotum than
through the skin anywhere else in the body [14]. This makes it
an extremely economic route for treatment, with a good safety
record over 10 years when applied as a patch [15].
AndroForte cream 2% Lawley Pharmaceuticals (84
patients, 141 treatment years) was applied to the scrotum as
a 1–2-cm length on a measuring stick once or twice daily
according to the clinical response. It proved convenient to use
and was non-irritant.
There was good symptom relief, with a moderate rise in
TT, which combined with a slight reduction in SHBG
produced a marked rise in CFT (Table 1; Figure 4f). E2
was raised, and LH and FSH markedly suppressed.
Glucose and TG were unchanged, cholesterol slightly
reduced, with no change in the HDL or ratio (Table 2). There
was no change in BMI, blood pressure or pulse rate, but the
hemoglobin and hematocrit were raised (Table 3).
Scrotal tostran (ST)
Unlike testogel which is irritant when applied to the thin skin
of the scrotum, Tostran 2% testosterone gel (Prostrakan, 113
patients, 118 treatment years) can be safely applied in that
region as one or two 10 mg pump applications once or twice
daily and gave good symptom relief (Table 1; Figure 4g). As
absorption of the gel was rapid, blood samples taken usually
1–2 h after application showed levels well up in the physio-
logical range or briefly higher. Though the SHBG was
unchanged, this gave significantly increased cFT and estrogen
levels, with suppression of LH and FSH.
Glucose and triglyceride levels were unchanged, but total
cholesterol, HDL, the LDL and cholesterol/HDL ratio were
significantly reduced (Table 2). BMI was slightly raised but
the systolic blood pressure was unchanged, while the diastolic
was reduced and pulse rate increased (Table 3). Hemoglobin
and hematocrit increased significantly, but again were usually
within the normal range.
Treatment group comparison
Comparing the different testosterone replacement therapies,
the unadjusted rates for failure to achieve complete symptom
response with TJ, TI, ST, TG, SA,TU and ME are 18, 23, 21,
35, 35, 49 and 59% at 1 year, and 24, 30, 35, 45, 52, 61 and
70% at 2 years, respectively. Hazard ratios by Cox
Regressions for failure relative to ME are 26, 34, 38, 53, 64
and 76% for TJ, TI, ST, TG, SA and TU, respectively
(p50.02). The differences in treatment failure between
treatment groups are shown by the Kaplan–Meier analysis,
as seen in Figure 5.
Discussion
This study showed that good symptomatic relief can be
obtained by a wide variety of testosterone preparations,
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Figure 5. Kaplan–Meier retention estimates by treatment preparation
(TI¼ testosterone implant, TU¼ oral testosterone undecanoate,
ME¼mesterolone, TG¼ testogel, TJ¼Nebido, SA¼ Scrotal
Andromen and ST¼ Scrotal Tostran).
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but there are significant differences in a full symptomatic
response to treatment between preparations.
Overall, safety factors monitored using these preparations,
including renal and liver function tests, remained normal.
In few cases, generally on pellet implants or Testogel, where
polycythemia with excessive increases in hemoglobin or
hematocrit occurred, this could be reversed by phlebotomy,
reducing the dosage or switching to another preparation. The
absence of adverse prostate changes or increases in PSA in
this study has been reported previously [16].
This study showed that good relief of the symptoms of
testosterone deficiency could be safely obtained over
extended periods by all seven of these preparations in spite
of the wide variations in the resulting endocrine profiles.
However, the more recently introduced creams and injections
are not only convenient but, with the scrotal route of
application Androforte and Tostran, also can be extremely
economic, greatly improving the cost/benefit ratio of testos-
terone treatment [17,18] (Table 4).
With the exception of the mesterolone group, who were
younger and had slightly fewer symptoms of androgen
deficiency, the pre-treatment endocrine, glucose, lipid and
cardiac risk factor values were similar, making the effects of
the different treatments more comparable.
The reductions in LH are taken as representing the
suppression of endogenous testosterone synthesis, while
those in FSH reflect the variable reduction in spermatogenesis
caused by the individual preparations. This may explain the
varied effects of different preparations on fertility. While the
pre-treatment LH levels were generally in the normal range,
the corresponding FSH levels tended towards the upper end of
the reference range, with some markedly raised levels in those
cases where there was long-standing testicular damage.
It is appreciated that there are several unavoidable
potential sources of bias in this study, most of which are
inherent in long-term studies in clinical practice. Firstly, the
findings could be biased towards cases which respond well
clinically and therefore continued on treatment. However, as
far as possible, patients who did not respond to their initial
treatment in doses titrated against symptoms were provided
with another preparation which gave the required relief.
Secondly, a general medical approach to treatment was
used, with advice and encouragement where needed in
relation to reducing stress, alcohol and weight, as well as
increasing physical activity and other life-style modifications.
Some of these goals were often difficult for the patient to
achieve and maintain even with the improved mood and
energy induced by testosterone treatment. Also, where there
were other clinical conditions needing intervention, such as
hypertension, hyperlipidemia or diabetes [19], the additional
treatment given may have distorted the response attributable
to testosterone alone.
Thirdly, the patients did not live in a controlled and stable
experimental setting, and over the many years of treatment
patients and their partners could be subject to major life
events which may, in some cases, have influenced their
responses to the particular form of testosterone being taken at
the time. Such major life events included relationship break-
ups, job-losses, retirement, major illnesses and bereavement.
In general, however, the large number of cases studied would
tend to even out effects due to these extraneous influences.
Despite the very different endocrine profiles produced by
the seven preparations studied, a good symptomatic response
could be produced and maintained by all of them, though
mesterolone had the weakest action and tended to be used in
younger patients who wished to retain fertility and avoid
gynecomastia during treatment.
This was seen by sustained decreases in the symptom
checklist score that the patients noticed the return of
symptoms when they discontinued treatment, and the fact
that many remained on the treatment for periods up to 20
years. This is not pattern of response which would be
expected of a placebo, which is typically transient. Their
sustained reversal also refutes the notion that the symptoms
are an untreatable effect of aging or are to be dismissed as
normal.
Though the diagnosis and treatment of testosterone
deficiency are often mainly based on TT, the key fact clearly
demonstrated in this study is that there is virtually no
relationship between diagnostic symptoms and initial total
testosterone, or any other endocrine variable such as cFT or
LH. Nor is any level of these hormones predictive of failure
to relieve the symptoms of testosterone deficiency by any of
the androgen preparations.
In other published studies reporting symptom response to
testosterone implants, ‘‘time of return of androgen deficiency
symptoms and the blood total and free testosterone concen-
trations are highly reproducible within individuals, but vary
markedly between men, indicating that each person had a
consistent testosterone threshold that may differ significantly
between individuals’’ [20] The same workers also observe
that ‘‘Some androgen-dependent biological functions require
higher plasma T levels than others, and these thresholds differ
among men’’. This later observation has been confirmed
by other researchers [21] who state ‘‘There is no evidence that
Table 4. % Absorption, theoretical benefits, practical benefits, average monthly cost of product (£UK), average monthly cost of
application, e.g. implant or injection (£UK) and total monthly cost of treatment (£UK) of seven different treatments.
Testosterone preparation % Absorption Theory Practice Product cost Application cost Total
Testosterone pellet implant (TI) 100 * ** 14 50 64
Oral testosterone undecanoate (TU) 10 * ** 34 0 34
Proviron (ME) 10 * ** 30 0 30
Testogel (Androgel) (TG) 15 *** *** 32 0 32
Nebido (TJ) 100 ** *** 40 5 45
Scrotal Cream (AndroForte-SA) 70 *** *** 24 0 24
Scrotal Gel (Tostran-ST) 70 *** *** 15 0 15
*Low, **Medium, ***High.
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a uniform structure of testosterone concentrations and com-
plaints exists within the cohort of elderly male patients’’ and
would again suggest that regulation of treatment according to
symptomatic response is preferable to that based on achieving
target TT levels.
A similar approach has recently been advocated by
Maganty et al. who suggest ‘‘the search for a discrete
threshold may be futile given emerging evidence. Recent
studies suggest that testosterone threshold varies by symp-
toms and among individuals. In addition, thresholds may vary
between young and old men. Therefore, initiation of treatment
should rely more on symptoms and less on a discrete
numerical threshold’’ [22].
The study was initiated before guidelines were started and
is unique in that the diagnosis was made predominantly on
history, clinical findings and symptoms, even when initial
androgen levels were within contemporaneous so-called
normal ranges. This remarkable finding is explained by the
theory of androgen resistance where, as with insulin in dia-
betes, there can be a relative rather than absolute deficiency
[23].
It is the complexities in the production and action of
testosterone, its metabolites, especially dihydrotesterone
(DHT) and oestradiol (E2), together with the variable tissue
levels and potential for local synthesis, which suggests the
case for the diagnosis and treatment of this condition
predominantly on the basis of the assessment and relief of
symptoms.
This suggestion is in accordance with an emerging
consensus that ‘‘expert opinions differed from some pub-
lished guidelines by the emphasis on symptoms as paramount,
recognition of the limitations of total T as a diagnostic test,
and the potential utility of a therapeutic trial in symptomatic
cases with normal total T concentrations’’ [9].
While TT and cFT are markedly and consistently raised by
treatment with implants and testosterone gels and are easily
measurable, treatment with oral preparations may rely more
on reductions in SHBG in the case of oral testosterone
undecanoate (TU) or a rise in DHT and reduction in estrogens
with mesterolone. Both oral TU and transdermal testosterone
gels cause doubling or trebling of DHT levels.
The increase in E2 due to aromatization, which is greatest
on Testogel, reduces testosterone synthesis and may explain
the ‘‘honey-moon’’ effect on beginning treatment. This is
sometimes seen when, after an excellent initial response,
the effectiveness of this treatment decreases within a month
or two, and cannot be restored, or may even be worsened,
by raising the dose. In some cases, efficacy can be restored
by giving an aromatase inhibitor, such as anastrazole, which
a few clinicians are using on its own to treat testosterone
deficiency.
There was no clinical evidence of either increased
cardiovascular events or venous thrombosis in this series,
and an adverse effect on coagulation factors was not found
even with high dosage of testosterone in early studies of TRT
used as a male contraceptive [24].
Zinc supplements are also reputed to decrease aromatiza-
tion, possibly through reduced circulating luteinizing hor-
mone and testosterone concentrations, alterations in hepatic
steroid metabolism, and modification of sex steroid hormone
receptor levels and the activity of their zinc fingers, though
evidence for this is limited [25].
Human chorionic gonadotrophin (hCG) has been shown
to be an effective form of treatment and has the benefits of
promoting physiological increase in endogenous testosterone
production, without suppression of gonadotrophins with
concomitant decrease in fertility seen with other forms of
androgen replacement. This approach may come to be the
standard form of treatment when the problem of the frequent
injections required has been resolved and could even lead to
‘‘androversion’’ in some patients, which is when other forms
of treatment are no longer required.
Conclusions
This long-term study of the evolution of different forms of
testosterone treatment has shown widely different endocrine
patterns between the seven preparations used, but also
demonstrated their inherent safety overall. Safety in relation
to the prostate has been shown in a previous publication from
this series [16], with no significant rise in PSA other than that
due to age, and no increase in the incidence of prostate cancer.
In this study, the overall effects of all the treatments on
metabolic and cardiac risk factors are shown to be neutral or
even beneficial, especially in relation to total cholesterol
and diastolic blood pressure. The FDA recognizes the issues
relating to biochemical threshold, and in relation to the
limitations of currently available published information, the
authors are pleased to be able to contribute to the debate and
present new informative data, without presuming to challenge
the position of the FDA.
It is hoped that this data, together with the favorable
clinical reports over the last 20 years [26], will prove
reassuring to the FDA and other doctors world-wide who have
been alarmed by the alleged but unsubstantiated cardiovas-
cular risks of testosterone treatment [26].
In particular, this study gives further evidence against the
use of very low-testosterone levels to deny TRT to men with
obvious symptoms. In Australia, this year the Pharmaceutical
Benefits Scheme has introduced regulations to dictate that
under their rules, TRT shall not be provided to men whose
total testosterones are above 6 nmol/l (173 ng/dl) in two
samples, half the levels suggested by ISSAM [27] and ISSM
guidelines, and then treatment can only be initiated by a
hospital consultant endocrinologist or urologist. The UK is
following similar restrictive policies on prescribing. Apart
from inflating the cost of diagnosis and treatment, this
conflicts with findings published by the instigators of these
guidelines on three important issues.
These are firstly that seven different Australian labora-
tories produced results that differ by up to 100%, i.e. a sample
containing 8 nmol/l TT as measured by the reference measure
of gas chromatography/mass spectrometry, can give readings
of between 5 and 12 nmol/l by far commoner and cheaper
immunoassays [28], i.e. ‘‘major differences exist between
commercial T immunoassays as well as divergence from the
GC/MS standard’’ [29] and between reference ranges accord-
ing to arithmetic, geometric and quoted laboratory values.
Secondly, the same authors have shown that ‘‘each person had
a consistent testosterone threshold for androgen deficiency
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symptoms that differed markedly between individuals’’ [20],
and finally ‘‘in older men an optimal plasma testosterone
is associated with reduced all-cause mortality and higher
dihydrotestosterone with reduced ischemic heart disease
mortality’’ [30].
However, the findings in the present study suggest that
with appropriate and necessary monitoring of safety param-
eters, testosterone treatment appears safe and economic.
Many men who could benefit in terms of symptom relief, with
improvement in related clinical conditions and prevention of
the long-term effects of testosterone deficiency, may remain
untreated because of excessive reliance on laboratory meas-
ures of androgens for diagnosis and treatment alongside
unwarranted safety concerns.
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